AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Trophoblast glycoprotein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q13641

UPID:

TPBG_HUMAN

Alternative names:

5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; M6P1; Wnt-activated inhibitory factor 1

Alternative UPACC:

Q13641; A8K555

Background:

The Trophoblast glycoprotein, known by alternative names such as 5T4 oncofetal antigen and Wnt-activated inhibitory factor 1, plays a crucial role in cellular processes. It is identified by the unique identifier Q13641 and is implicated in modulating Wnt/beta-catenin signaling. This modulation is achieved through its indirect interaction with LRP6, which prevents the internalization of Wnt3a, thus acting as a signaling inhibitor.

Therapeutic significance:

Understanding the role of Trophoblast glycoprotein could open doors to potential therapeutic strategies. Its involvement in the Wnt/beta-catenin pathway, a key regulator of cell proliferation and differentiation, highlights its potential as a target for therapeutic intervention in diseases where this pathway is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.